Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines
This agreement enhances Multicare's oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.
Mumbai: Global pharma major, Lupin Limited and DKSH announced today that they have signed an exclusive license and supply agreement to commercialize five of Alvotech's proposed biosimilars in the Philippines.
The biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml), Xgeva (denosumab 70 mg/ml), Simponi (golimumab), and Eylea (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.
According to the agreement, Lupin's subsidiary in the Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for the distribution and commercialization of the biosimilars once approved. These reference products are used to treat disorders relating to bone disease, oncology, immunology, and ophthalmology. This agreement enhances Multicare's oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.
"We are pleased to announce the addition of five new biosimilar candidates to our portfolio, which will provide patients in the Philippines with effective, high-quality, and affordable treatment options," said Gabriel Georgy, Regional Head Southeast Asia, Lupin.
Peter Dolinsky, Vice President Own Brands, Asia Pacific at DKSH added, "We are delighted to partner with Lupin and bring these important therapeutic offerings to patients in the Philippines. This partnership is in line with our purpose of enriching people's lives, and we are proud to be working with a strong local partner to make this happen."
Read also: Lupin Gets USFDA Nod For Generic Cancer Treatment Drug
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas.
